First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results
First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.
How this was made

The 30-second read
Why it matters
The data provide a catalyst that could drive short‑term buying interest while setting expectations for future readouts in 2027.
Market read
Early positive trial data are material for the stock and may attract speculative buying ahead of later‑stage trial announcements.
What to watch
No disclosed effect size; trial size may be small, limiting confidence in the result.
Background
First Tracks Biotherapeutics announced its first positive clinical readout for ANB033, a therapy targeting celiac disease, and outlined upcoming trial milestones and a recent $200 million private placement.
Ticker impact
First Tracks Biotherapeutics reported statistically significant positive Phase 1b results for ANB033 in celiac disease.
likely upside as market prices in the favorable trial readout
Phase 1b data are material for a biotech; no effect size disclosed but significance suggests progress toward later‑stage trials.
Market effects
Positive celiac disease data could boost interest in gut‑health biotech peers.
U.S. biotech sector may see modest lift.
Limited to biotech investors; no broad market effect.
Counterpoint
Early‑stage data may be over‑hyped; later trials could fail, risking a pull‑back.
Key entities
- companyFirst Tracks Biotherapeutics
U.S. biotech developing ANB033 for celiac disease and other indications.